Promising combo study for advanced breast cancer halted early
NCT ID NCT04504331
First seen Feb 17, 2026 · Last updated Jun 06, 2026 · Updated 11 times
Summary
This early-phase study tested a new drug (infigratinib) combined with tamoxifen for people with a specific type of advanced breast cancer (hormone receptor-positive, HER2-negative, with FGFR changes). The main goal was to find a safe dose by checking for side effects. Only 4 people took part before the study was stopped early, so we don't have clear results on how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Stanford, California, 94304, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.